76 related articles for article (PubMed ID: 26640129)
1. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
[TBL] [Abstract][Full Text] [Related]
2. Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
Akalestou E; Christakis I; Solomou AM; Minnion JS; Rutter GA; Bloom SR
Pancreas; 2016 Aug; 45(7):967-73. PubMed ID: 26731187
[TBL] [Abstract][Full Text] [Related]
3. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.
Daniele G; Iozzo P; Molina-Carrion M; Lancaster J; Ciociaro D; Cersosimo E; Tripathy D; Triplitt C; Fox P; Musi N; DeFronzo R; Gastaldelli A
Diabetes; 2015 Oct; 64(10):3406-12. PubMed ID: 26116695
[TBL] [Abstract][Full Text] [Related]
4. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.
Mitchell JL; Lyons HS; Walker JK; Yiangou A; Grech O; Alimajstorovic Z; Greig NH; Li Y; Tsermoulas G; Brock K; Mollan SP; Sinclair AJ
Brain; 2023 May; 146(5):1821-1830. PubMed ID: 36907221
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
Grech O; Mitchell JL; Lyons HS; Yiangou A; Thaller M; Tsermoulas G; Brock K; Mollan SP; Sinclair AJ
Eye (Lond); 2024 May; 38(7):1374-1379. PubMed ID: 38212401
[TBL] [Abstract][Full Text] [Related]
6. Secretin-stimulated ultrasound estimation of pancreatic secretion in cystic fibrosis validated by magnetic resonance imaging.
Engjom T; Tjora E; Wathle G; Erchinger F; Lærum BN; Gilja OH; Haldorsen IS; Dimcevski G
Eur Radiol; 2018 Apr; 28(4):1495-1503. PubMed ID: 29134356
[TBL] [Abstract][Full Text] [Related]
7. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.
Fiorentino TV; Owston M; Abrahamian G; La Rosa S; Marando A; Perego C; Di Cairano ES; Finzi G; Capella C; Sessa F; Casiraghi F; Paez A; Adivi A; Davalli A; Fiorina P; Guardado Mendoza R; Comuzzie AG; Sharp M; DeFronzo RA; Halff G; Dick EJ; Folli F
Am J Pathol; 2015 Jan; 185(1):139-50. PubMed ID: 25447052
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.
Leggio L; Hendershot CS; Farokhnia M; Fink-Jensen A; Klausen MK; Schacht JP; Simmons WK
Nat Med; 2023 Dec; 29(12):2993-2995. PubMed ID: 38001271
[No Abstract] [Full Text] [Related]
9. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E
Diabetes Obes Metab; 2024 Mar; 26(3):1137. PubMed ID: 37997518
[No Abstract] [Full Text] [Related]
10. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
13. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
Calsolaro V; Edison P
CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
[TBL] [Abstract][Full Text] [Related]
14. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.
Parveen R; Agarwal NB; Kaushal N; Mali G; Raisuddin S
Expert Opin Pharmacother; 2016; 17(1):105-15. PubMed ID: 26650511
[TBL] [Abstract][Full Text] [Related]
16. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
17. Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.
Smits MM; Bunck MC; Diamant M; Corner A; Eliasson B; Heine RJ; Smith U; Yki-Järvinen H; van Raalte DH
Diabetes Care; 2016 Mar; 39(3):e42-3. PubMed ID: 26721816
[No Abstract] [Full Text] [Related]
18. Subcutaneous nodules secondary to exenatide once weekly: clinical and histological findings.
Donato S; Sargento D; Soares-de-Almeida L; Uva L
Acta Diabetol; 2016 Aug; 53(4):681-2. PubMed ID: 26695174
[No Abstract] [Full Text] [Related]
19. Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting.
Nonogaki K; Kaji T; Yamazaki T; Murakami M
Neurosci Lett; 2016 Jan; 612():14-17. PubMed ID: 26683903
[TBL] [Abstract][Full Text] [Related]
20. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
